What is ImmuCell Corporation (ICCC)?

ImmuCell Corporation (ICCC) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ICCC?

The current price of ICCC is $10.32. Prices are updated in real time on Stocks360.

What is ICCC's price-to-earnings (PE) ratio?

ICCC's trailing twelve-month PE ratio is 121.99, based on current price and earnings per share data available on Stocks360.

What is ICCC's market capitalization?

ICCC's market capitalization is $93,728,273.00, placing it in the small-cap tier.

ImmuCell Corporation (ICCC)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$10.32

Market Cap

$93.73M

PE (TTM)

121.99

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.57

Day Range

$10.25 – $10.57

52-wk Range

$4.52 – $12.10

Avg Volume

N/A

Volume

3.17K

ImmuCell Corporation (ICCC) is a publicly traded company in the Healthcare sector. Latest price: $10.32. Market cap $93.73M. Trailing PE 121.99. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 7 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-30 · $6.09 2026-10-29 · $10.32 (+69.46%)

Earnings

Most Recent

Aug 13, 2026

EPS $0.20 vs est. $0.05

Beat by $0.15

Next Earnings

Nov 12, 2026

EPS estimate $0.05

Proprietary Signals

Signal snapshot temporarily unavailable.

About ImmuCell Corporation

ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	121.99×
P/S (TTM)	3.06×
P/B	2.98×
P/FCF (TTM)	22.24×
EV / EBITDA	27.52×
EV / Sales	3.17×
Earnings Yield	0.84%
Free Cash Flow Yield	4.50%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$97.32M
Revenue (TTM)	$30.68M
Net Income (TTM)	$788.89K
Free Cash Flow (TTM)	$4.61M
Net Debt	$3.59M
Working Capital	$16.64M
Gross Margin	40.32%
Operating Margin	12.60%
Net Margin	2.57%
Return on Equity	2.68%
Return on Invested Capital	8.14%